Can a special sunscreen stop skin spots from turning dangerous?

NCT ID NCT07335003

Recruiting now Prevention Sponsor: Cosmetique Active International Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new sunscreen, Anthelios Fluide 100 KA+ UVMune 400, can help prevent actinic keratosis—rough, scaly patches that can turn into skin cancer—in people aged 60 and older who already have many of these spots. Eighty participants will be randomly assigned to use the sunscreen daily or follow standard sun protection. The main goal is to see if the sunscreen reduces the number of new lesions over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anthelios Fluide 100 KA+ UVMune 400 sunscreen
What this could lead to: If it works, this could show that a specific sunscreen helps prevent actinic keratosis lesions from forming or worsening.
What could go wrong: This is a small, early-stage study (80 people) testing a cosmetic product, not a drug. Results may not apply to everyone, and the benefit over standard sun protection is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTINIC KERATOSIS (AK) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

actinic keratosis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACTINIC KERATOSIS (AK)

Contacts and locations

Locations

Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital
RECRUITING

Camperdown, New South Wales, 2050, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.